Navigation Links
Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
Date:9/14/2009

SUNNYVALE, Calif., Sept. 14 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that it will report financial results for the fourth quarter and fiscal year ended June 30, 2009 after the NASDAQ market closes on Thursday September 17, 2009 at 1:30 p.m. PDT (4:30 p.m. EDT). To participate in the conference call, please dial 866-642-7062 for domestic callers and 706-643-1591 for international callers. The conference ID is 30472935. To access the audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. The archived version of the webcast will be available on the company's website for one month.

About Pharmacyclics

Pharmacyclics(R) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The Company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
2. Pharmacyclics, Inc. Rights Offering Oversubscribed
3. Pharmacyclics Announces Subscription Price for Rights Offering
4. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
5. Pharmacyclics Files Registration Statement for Rights Offering
6. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
7. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
8. Pharmacyclics Secures $5.0 Million in Debt Financing
9. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
10. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
11. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 /PRNewswire-iReach/ -- A case study ... between the school,s bioengineering department and the Intel® ... Intel® Software Academic Program, UCSD,s research focuses on ... human body.  Photo - ... the work of Dr. Todd P. Coleman ...
(Date:8/19/2014)... Piscataway, NJ (PRWEB) August 20, 2014 ... engineering and regenerative medicine is an inadequate vascular ... engineered constructs and decellularized tissues is critical for ... Researchers have attempted to mitigate deficiencies in vascularization ... including adding scaffold bioactivity, optimizing scaffold design and ...
(Date:8/19/2014)... Calif. (PRWEB) August 19, 2014 ... campaign to raise $200,000 to fund a corporate ... device. , This development is a critical ... model of care to the implementation of personalized ... method of practicing medicine. , Indiegogo contributions will ...
(Date:8/19/2014)... 19, 2014 Research and ... the "Spectroscopy Equipment and Accessories - ... their offering. This report ... and Accessories in US$ Thousands by the ... Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) ...
Breaking Biology Technology:Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2
... , , SEATTLE, Aug. 11 ... 2 clinical trial of OMS302, the Company,s ophthalmologic PharmacoSurgery(TM) ... anti-inflammatory agent and an agent that causes pupil dilation ... , Omeros, Phase 1/Phase 2 trial ...
... , , SEATTLE, Aug. 11 ... quarter ended June 30, 2009. Revenue for the second quarter of 2009 ... Revenue for the six months ended June 30, 2009 was $55,000 compared to ... Dendreon,s total operating expenses for the second quarter of 2009 were ...
... Diverse Student ... , ... 11, 2009 - As a new class of eager high school seniors begins the college ... mark, a new study reveals what Americans consider to be the defining characteristics of a ...
Cached Biology Technology:Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery 2Dendreon Reports Second Quarter 2009 Financial Results 2Dendreon Reports Second Quarter 2009 Financial Results 3Dendreon Reports Second Quarter 2009 Financial Results 4Dendreon Reports Second Quarter 2009 Financial Results 5Dendreon Reports Second Quarter 2009 Financial Results 6What Makes a University Great? Americans Say Renowned Faculty, Top-Rank Research Center are Most Important, According to New Survey from IP Advocate 2What Makes a University Great? Americans Say Renowned Faculty, Top-Rank Research Center are Most Important, According to New Survey from IP Advocate 3What Makes a University Great? Americans Say Renowned Faculty, Top-Rank Research Center are Most Important, According to New Survey from IP Advocate 4What Makes a University Great? Americans Say Renowned Faculty, Top-Rank Research Center are Most Important, According to New Survey from IP Advocate 5
(Date:8/19/2014)... devised a new implantable tissue scaffold coated with bone ... weeks. When applied to bone injuries or defects, this ... bone that looks and behaves just like the original ... a dramatic improvement over the current standard for treating ... of the patient,s body a painful process that ...
(Date:8/19/2014)... infants born with neonatal abstinence syndrome (NAS) secondary ... time going through withdrawal than others, but the ... and epigenetic (when genes are turned on or ... factors, researchers at Boston University School of Medicine ... first of its kind study to identify some ...
(Date:8/19/2014)... The ancestors of today,s crocodiles colonised the seas during ... to a new Anglo-French study which establishes a link ... temperature over a period of more than 140 million ... Martin from the Universit de Lyon, France and formerly ... week in Nature Communications ., Today, crocodiles are ...
Breaking Biology News(10 mins):Engineering new bone growth 2Engineering new bone growth 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2Evolution of marine crocodilians constrained by ocean temperatures 2
... age-old tradition that dates back at least 8,000 years ... about the bacteria responsible for turning milk into cheese., ... has identified a new line of bacteria they believe ... cheeses. , The team used DNA fingerprinting techniques to ...
... 6, 2009 Elsevier, a leading global healthcare and ... in the Elsevier Grand Challenge, a competition inviting ... amount of online life sciences information. ( ... on December 15th at the Massachusetts Institute of ...
... 2009, St. Louis, MO As adolescents mature into young adults, ... impact eating habits in a negative way. In a study published ... American Dietetic Association , researchers observed that while young adults enjoy ... 42% of females reported lacking time to sit down and eat ...
Cached Biology News:Wonderful cheese is all in the culture 2Finalists announced in the Elsevier Grand Challenge 2Finalists announced in the Elsevier Grand Challenge 3Young adults need to make more time for healthy meals 2
BD BaculoGold Max-XP Insect Cell Medium 1 Liter...
Newborn Bovine Serum Heat-Inactivated...
Performance, mycoplasma, virus, and endotoxin tested...
Bethyl Laboratories Ready-To-Use IHC Bluing Reagent is used following IHC hematoxylin counterstaining with immunohistochemical procedures. Shelf-Life: 1 year from date of receipt...
Biology Products: